PRF Technologies Ltd. current report, Q2 FY2024

Full document

Business Context and Reporting Period

Company: PainReform Ltd. (PRF Technologies Ltd.)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: April 17, 2024
Context: The Company entered into a definitive securities purchase agreement on April 15, 2024, for a public offering on a reasonable best efforts basis. The offering is expected to close on or about April 18, 2024.

Key Financial Metrics and Transaction Details

Offering Structure:

  • Ordinary Shares: 447,500 shares at $0.80 per share.
  • Pre-Funded Warrants: 4,552,500 warrants at $0.7999 per warrant (exercisable at $0.0001).
  • Investor Warrants: 5,000,000 warrants at $0.80 exercise price, exercisable until April 18, 2029.
Proceeds:
  • Gross Proceeds: Approximately $4.0 million before deducting estimated offering expenses.
  • Use of Proceeds: To advance clinical studies and for general corporate purposes.
Placement Agent Fees (H.C. Wainwright & Co., LLC):
  • Cash Fee: 7.0% of gross proceeds.
  • Management Fee: 1.0% of gross proceeds.
  • Expenses: Reimbursement for non-accountable expenses ($50,000), legal fees (up to $100,000), and clearing expenses (up to $15,950).
  • Warrant Fee: 350,000 Placement Agent Warrants (7.0% of Shares + Pre-Funded Warrants) at $1.00 exercise price.
Existing Warrant Amendment:
  • Amendment to 935,792 December 2023 Warrants: Exercise price reduced to $0.80; expiration extended to five years post-closing.
Financial Metrics:

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses solely on the capital raise transaction.

Material Changes and Restrictions

Transaction Restrictions:

  • Variable Rate Transaction Lock-up: One-year prohibition on entering into variable rate transactions following the closing.
  • Standstill: 60-day standstill restrictions for investors following the closing.
Capital Structure Impact:
  • Significant dilution potential due to the issuance of shares, pre-funded warrants, and investor warrants.
  • Reduction in exercise price for existing December 2023 warrants.

Outlook, Risks, and Contingencies

Outlook:

  • Proceeds are intended to fund clinical studies, indicating a focus on product development.
Risks and Contingencies:
  • Closing Conditions: The offering is subject to customary closing conditions; failure to satisfy these may prevent the offering from closing.
  • Forward-Looking Statements: The Company warns that forward-looking statements regarding the closing date and use of proceeds are not guaranteed.
  • Regulatory: The offering is made pursuant to a registration statement on Form F-1 declared effective on April 15, 2024.

Investor Verification Checklist

  • Verify the final closing date of the offering (expected April 18, 2024) and total net proceeds after expenses.
  • Confirm the exact number of shares issued and the resulting fully diluted share count.
  • Review the full text of the Securities Purchase Agreement and Warrant Amendment (Exhibits 10.1 and 10.5) for specific covenants.
  • Assess the impact of the 7.0% cash fee and 1.0% management fee on the net capital raised.
  • Monitor the status of the clinical studies to be funded by the proceeds.